Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Submission of Matters to a Vote of Security Holders

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item5.07

Submission of Matters to a Vote of Security
Holders.

Agios Pharmaceuticals, Inc. (the Company) held its Annual Meeting
of Stockholders on June13, 2017. The following is a summary of
the matters voted on at that meeting.

1. The Companys stockholders elected Dr.LewisC. Cantley, Ph.D.,
Mr.PaulJ. Clancy and Mr.IanT. Clark as class I directors,
each to serve for a three-year term expiring at the 2020
Annual Meeting of Stockholders and until his successor has
been duly elected and qualified. The results of the
stockholders vote with respect to the election of such class
I directors were as follows:
Votes For Votes Withheld Broker Non-Votes

Dr.Lewis C. Cantley, Ph.D.

31,734,840 550,548

Mr.PaulJ. Clancy

32,100,022 185,366

Mr.IanT. Clark

31,245,540 1,039,848
2. The Companys stockholders approved the non-binding, advisory
vote on the compensation paid to its named executive
officers. The results of the stockholders non-binding, advisory vote
with respect to compensation paid to the Companys named
executive officers were as follows:

Votes For

Votes

Against

Votes

Abstaining

Broker

Non-Votes

26,261,131

6,000,355 23,902


About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.

An ad to help with our costs